Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

0.8117
+0.00911.13%
Post-market: 0.82000.0083+1.02%19:55 EDT
Volume:783.63K
Turnover:598.06K
Market Cap:13.43M
PE:-0.18
High:0.8872
Open:0.7900
Low:0.7583
Close:0.8026
52wk High:12.23
52wk Low:0.7583
Shares:16.54M
Float Shares:11.46M
Volume Ratio:3.33
T/O Rate:6.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5617
EPS(LYR):-19.4955
ROE:-931.14%
ROA:-79.37%
PB:-12.32
PE(LYR):-0.04

Loading ...

Company Profile

Company Name:
Tempest Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
4
Office Location:
2000 Sierra Point Parkway,Suite 400,Brisbane,California,United States
Zip Code:
94005
Fax:
- -
Introduction:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Directors

Name
Position
Matthew Angel
Chief Executive Officer and Director and President

Shareholders

Name
Position
Matthew Angel
Chief Executive Officer and Director and President
Nicholas Maestas
Chief Financial Officer and Corporate Secretary and Head of Corporate Strategy
Justin Trojanowski
Corporate Controller and Principal Accounting Officer